查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1963895

被忽視的熱帶疾病治療市場－全球產業規模、佔有率、趨勢、機會、預測：按疾病、產品、地區和競爭對手分類，2021-2031年

Neglected Tropical Disease Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Disease, By Product, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球被忽視的熱帶疾病 (NTD) 治療市場預計將從 2025 年的 79.9 億美元成長到 2031 年的 111.9 億美元，複合年成長率達到 5.77%。

該市場涉及用於對抗熱帶地區流行感染疾病（例如土源性蠕蟲病和淋巴絲蟲病）的藥品和醫療干預措施的研發和供應。該領域的成長主要得益於跨國製藥公司的大規模藥品捐贈計畫以及支持研究和藥品取得的慈善組織的大量資金投入。此外，政府主導的大規模藥品管理舉措也提供了至關重要的基礎，確保了對治療藥物的穩定需求，並保證了向高風險族群的系統性供應。

市場概覽
預測期 2027-2031
市場規模：2025年 79.9億美元
市場規模：2031年 111.9億美元
複合年成長率：2026-2031年 5.77%
成長最快的細分市場 登革熱
最大的市場 北美洲

然而，許多流行地區的醫療基礎設施不足，嚴重阻礙了市場擴張，並給偏遠社區的「最後一公里」配送造成了嚴重的物流限制。這些供應鏈缺陷經常擾亂治療計劃，並限制了全球衛生計畫的有效覆蓋範圍。根據國際藥品製造商協會聯合會（IFPMA）統計，2023年全球約有9億人接受了被忽視的熱帶疾病治療。這項數據凸顯了在物流障礙持續存在的情況下，管理這些疾病所需的龐大營運規模。

市場促進因素

世界衛生組織2030年藍圖及其根除目標的策略性實施將成為重要的市場催化劑，推動全球行動的重點從疾病控制轉向徹底阻斷傳播。這項政策架構鼓勵各國政府將被忽視的熱帶病防治項目納入核心衛生系統，從而增加對認證所需的基本診斷工具和治療方法的採購。藍圖強調可衡量的里程碑，因此需要持續滿足治療後監測技術的需求，並維持藥品儲備，直到確認根除為止。正如2024年12月發布的《攜手抗擊被忽視的熱帶病2024：年度回顧》報告所述，全球努力已取得重大進展，已有54個國家根除了至少一種被忽視的熱帶病，這鞏固了市場向根除需求驅動型發展的方向。

此外，世界衛生組織增加的資金和津貼，以及強力的公私合營，確保了資源匱乏地區藥品生產和分發所需的流動資金。由於該領域的商業性回報有限，慈善資金和企業捐贈對於維持吡喹酮和阿苯達唑等關鍵藥物的供應鏈至關重要。這些合作計畫不僅資助新療法的研究，還補貼大規模給藥計畫的物流成本，從而彌合生產和病患取得之間的差距。根據被忽視的熱帶疾病根除聯盟於2024年10月發布的《基加利被忽視的熱帶疾病宣言：2022-2024年進展報告》，國際合作夥伴已籌集17億美元用於實現這些目標。此外，衛材株式會社報告稱，到2025年，已累計向流行地區提供了25.1億片乙胺嗪片，這充分展現了企業為支持市場穩定所做的巨大貢獻。

市場挑戰

流行地區醫療基礎設施的匱乏嚴重阻礙了被忽視的熱帶疾病（NTD）治療藥物全球市場的發展。這項挑戰表現為嚴重的物流瓶頸，在基本藥物到達最終目的地之前就造成了供應鏈中斷。在許多受影響地區，缺乏可靠的運輸網路、溫控儲存設施和設備齊全的當地診所，阻礙了治療藥物的穩定供應。即使國際捐贈項目能夠購買大量藥品，這些基礎設施的不足也常常導致當地倉庫出現缺貨和藥品過期的情況。因此，市場無法將現有庫存轉化為實際的治療，失去了維持全球衛生舉措所需的營運動力。

這些後勤保障方面的失誤直接導致所需醫療干預規模與實際接受治療的患者人數之間持續存在差距，使得很大一部分人口無法獲得醫療保健，並限制了可覆蓋的市場規模。根據世界衛生組織（世衛組織）2024年的報告，全球約有16.2億人需要治療被忽視的熱帶疾病（NTD）。這項數據凸顯了當前很大一部分需求仍未滿足的現狀，這主要是由於缺乏提供醫療服務的必要手段，即便已有治療方法。這種供不應求會降低大規模藥物宣傳活動的有效性，並阻礙未來的投資成長，從而抑制市場發展。

市場趨勢

針對兒童適用的兒童製劑和劑型的研發正成為一項關鍵趨勢，旨在解決流行地區幼兒治療的不平等問題。傳統上，由於缺乏適合學齡前兒童的藥物選擇，大規模用藥宣傳活動受到阻礙，常常導致成人藥片被不準確地碾碎，從而影響安全性和用藥依從性。如今，製藥公司正優先研發可分散、口感良好的片劑，以確保劑量準確，並方便這一弱勢族群服用。例如，默克公司在2025年3月發布的新聞稿《首次在學齡前兒童中使用阿普拉喹酮（一種兒童寄生蟲病治療藥物）》中報告稱，在烏干達的一項研究中，他們成功使用了新開發的可分散片劑，這表明市場在為兒童提供全面治療方面取得了進展。

同時，產品開發夥伴關係（PDP）作為一種主要的研發模式，其蓬勃發展正在重塑創新格局，並有效規避了缺乏商業性獎勵而限制私部門投資的問題。這些聯盟將製藥公司、學術機構和慈善組織的資源整合到一個虛擬的研究引擎中，成功地推動了新型化合物的發現和再利用。這種合作框架對於維持可行的治療藥物研發管線至關重要，而任何一家公司都無法獨自承擔這項重任。被忽視疾病藥物研發舉措（DNDi）就是這一趨勢的顯著例證。該組織在2025年7月發布的2024年度報告中指出，其管理46個研發計劃，其中21個項目致力於新型化學物質的辨識或開發。這凸顯了PDP模式在確保未來治療方法的優勢。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：被忽視的熱帶疾病（NTDs）治療全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依類型分類的疾病（登革熱、狂犬病、沙眼、伯氏潰瘍、尤斯氏症、痲瘋病、南美錐蟲病、利什曼原蟲症病、土源性蠕蟲病、其他）
    • 依產品（藥品、疫苗）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美被忽視的熱帶疾病（NTDs）治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲被忽視的熱帶疾病（NTDs）治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區被忽視的熱帶疾病（NTDs）治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲被忽視的熱帶疾病（NTDs）治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲被忽視的熱帶疾病（NTDs）治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：被忽視的熱帶疾病（NTDs）治療的全球市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • F. Hoffmann-La Roche Ltd
  • Sanofi SA
  • Bayer AG
  • GlaxoSmithKline plc
  • Novartis AG
  • Pfizer, Inc.
  • Eisai Co., Ltd.
  • Astellas Pharma Inc.
  • Takeda Pharmaceutical Company Limited
  • Gilead Sciences, Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 25404

The Global Neglected Tropical Disease (NTD) Treatment Market is projected to expand from USD 7.99 billion in 2025 to USD 11.19 billion by 2031, achieving a compound annual growth rate of 5.77%. This market involves the creation and supply of pharmaceuticals and medical interventions aimed at combating communicable diseases common in tropical zones, such as soil-transmitted helminthiases and lymphatic filariasis. Growth in this sector is largely propelled by extensive medication donation programs organized by multinational pharmaceutical companies, along with significant financial support from philanthropic entities that subsidize research and access. Additionally, government-led mass drug administration initiatives serve as a crucial foundation, generating consistent demand for therapeutics and ensuring systematic delivery to at-risk populations.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 7.99 Billion
Market Size 2031USD 11.19 Billion
CAGR 2026-20315.77%
Fastest Growing SegmentDengue
Largest MarketNorth America

However, market expansion is significantly hindered by the inadequacy of healthcare infrastructure in many endemic regions, which imposes severe logistical constraints on last-mile delivery to isolated communities. These supply chain deficiencies frequently interrupt treatment schedules and restrict the effective reach of global health programs. According to the International Federation of Pharmaceutical Manufacturers & Associations, approximately 900 million individuals worldwide received treatment for a neglected tropical disease in 2023. This statistic underscores the immense operational scale required to manage these conditions, despite the persistent logistical obstacles complicating delivery efforts.

Market Driver

The strategic execution of the WHO 2030 Roadmap and Eradication Targets serves as a primary market catalyst, shifting the global operational focus from disease control to the complete interruption of transmission. This policy framework encourages national governments to incorporate NTD programs into their core health systems, thereby increasing the procurement of essential diagnostic tools and therapeutic regimens required for certification. The roadmap's emphasis on measurable milestones necessitates sustained demand for post-treatment surveillance technologies and the maintenance of medication stockpiles until elimination is verified. As reported by Uniting to Combat NTDs in their '2024: A year in review' released in December 2024, the global initiative achieved a critical milestone with 54 countries having eliminated at least one neglected tropical disease, confirming the market's trajectory toward eradication-driven demand.

Furthermore, increasing funding and grants from global health organizations, combined with robust public-private partnerships, provide the necessary financial liquidity for drug production and distribution in low-resource settings. Since commercial returns in this sector are limited, philanthropic capital and corporate donations are essential for sustaining the supply chain of critical medications like praziquantel and albendazole. These collaborative ventures not only finance research for new therapeutics but also subsidize the logistical costs of mass drug administration, bridging the gap between manufacturing and patient access. According to the 'Kigali Declaration on Neglected Tropical Diseases: 2022-2024 Progress Report' published by Uniting to Combat NTDs in October 2024, international partners have mobilized US$1.7 billion to support these goals. Additionally, Eisai Co., Ltd. reported in 2025 that it had provided a cumulative total of 2.51 billion diethylcarbamazine tablets to endemic regions, illustrating the vast scale of corporate contribution underpinning market stability.

Market Challenge

The deficiency of healthcare infrastructure in endemic regions constitutes a significant barrier to the growth of the Global Neglected Tropical Disease (NTD) Treatment Market. This challenge manifests as a severe logistical bottleneck where the supply chain for essential pharmaceuticals fractures before reaching the last mile. In many target areas, the absence of reliable transportation networks, climate-controlled storage facilities, and adequately equipped local clinics obstructs the consistent distribution of therapeutics. Even when international donation programs successfully mobilize vast quantities of medication, these infrastructure deficits frequently result in stockouts or product expiration at regional depots. Consequently, the market struggles to convert available inventory into administered treatments, stalling the operational momentum required to sustain global health initiatives.

The direct impact of these logistical failures is a persistent disconnect between the volume of medical interventions required and the actual number of patients served, which limits the addressable market size by rendering a significant portion of the population inaccessible. According to the World Health Organization, it was reported in 2024 that approximately 1.62 billion people globally required interventions for neglected tropical diseases. This statistic highlights that, despite the availability of treatments, a massive segment of the demand remains unmet primarily due to the inability to physically deliver care. This delivery shortfall impedes market expansion by reducing the efficacy of mass drug administration campaigns and discouraging the scaling of future investments.

Market Trends

The development of pediatric-specific formulations and child-friendly dosage forms is emerging as a crucial trend, addressing a historical treatment gap for younger demographics in endemic regions. Previously, mass drug administration campaigns were hindered by a lack of suitable options for preschool-aged children, often requiring the inaccurate crushing of adult tablets, which compromised safety and adherence. Pharmaceutical manufacturers are now prioritizing the engineering of dispersible, palatable tablets that ensure precise dosing and ease of administration for this vulnerable group. For instance, in March 2025, Merck announced in the press release 'First Preschool-Aged Child Receives Arpraziquantel for the Treatment of Schistosomiasis' that its newly developed dispersible tablet was successfully administered in an implementation study in Uganda, validating the market's progression toward inclusive therapeutic coverage for pediatric populations.

Simultaneously, the proliferation of Product Development Partnerships (PDPs) as the primary R&D model is structurally reshaping the innovation landscape, effectively circumventing the limited commercial incentives that restrict private sector investment. By consolidating resources from pharmaceutical companies, academic institutions, and philanthropic entities into a virtual research engine, these consortia are successfully driving the discovery of novel compounds and repurposing strategies. This collaborative framework is essential for maintaining a viable pipeline of therapeutics that individual corporations cannot sustain in isolation. Highlighting this trend, the Drugs for Neglected Diseases initiative (DNDi) noted in its '2024 Annual Report' released in July 2025 that it managed a diverse portfolio of 46 R&D projects, with 21 specifically focused on identifying or developing new chemical entities, underscoring the dominance of the PDP model in securing future treatments.

Key Market Players

  • F. Hoffmann-La Roche Ltd
  • Sanofi S.A.
  • Bayer AG
  • GlaxoSmithKline plc
  • Novartis AG
  • Pfizer, Inc.
  • Eisai Co., Ltd.
  • Astellas Pharma Inc.
  • Takeda Pharmaceutical Company Limited
  • Gilead Sciences, Inc.

Report Scope

In this report, the Global Neglected Tropical Disease (NTD) Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Neglected Tropical Disease (NTD) Treatment Market, By Disease

  • Dengue
  • Rabies
  • Trachoma
  • Buruli Ulcer
  • Yaws
  • Leprosy
  • Chagas Disease
  • Leishmaniasis
  • Soil-transmitted Helminthiases
  • Others

Neglected Tropical Disease (NTD) Treatment Market, By Product

  • Drugs
  • Vaccines

Neglected Tropical Disease (NTD) Treatment Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Neglected Tropical Disease (NTD) Treatment Market.

Available Customizations:

Global Neglected Tropical Disease (NTD) Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Neglected Tropical Disease (NTD) Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Disease (Dengue, Rabies, Trachoma, Buruli Ulcer, Yaws, Leprosy, Chagas Disease, Leishmaniasis, Soil-transmitted Helminthiases, Others)
    • 5.2.2. By Product (Drugs, Vaccines)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Neglected Tropical Disease (NTD) Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Disease
    • 6.2.2. By Product
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Neglected Tropical Disease (NTD) Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Disease
        • 6.3.1.2.2. By Product
    • 6.3.2. Canada Neglected Tropical Disease (NTD) Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Disease
        • 6.3.2.2.2. By Product
    • 6.3.3. Mexico Neglected Tropical Disease (NTD) Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Disease
        • 6.3.3.2.2. By Product

7. Europe Neglected Tropical Disease (NTD) Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Disease
    • 7.2.2. By Product
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Neglected Tropical Disease (NTD) Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Disease
        • 7.3.1.2.2. By Product
    • 7.3.2. France Neglected Tropical Disease (NTD) Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Disease
        • 7.3.2.2.2. By Product
    • 7.3.3. United Kingdom Neglected Tropical Disease (NTD) Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Disease
        • 7.3.3.2.2. By Product
    • 7.3.4. Italy Neglected Tropical Disease (NTD) Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Disease
        • 7.3.4.2.2. By Product
    • 7.3.5. Spain Neglected Tropical Disease (NTD) Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Disease
        • 7.3.5.2.2. By Product

8. Asia Pacific Neglected Tropical Disease (NTD) Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Disease
    • 8.2.2. By Product
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Neglected Tropical Disease (NTD) Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Disease
        • 8.3.1.2.2. By Product
    • 8.3.2. India Neglected Tropical Disease (NTD) Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Disease
        • 8.3.2.2.2. By Product
    • 8.3.3. Japan Neglected Tropical Disease (NTD) Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Disease
        • 8.3.3.2.2. By Product
    • 8.3.4. South Korea Neglected Tropical Disease (NTD) Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Disease
        • 8.3.4.2.2. By Product
    • 8.3.5. Australia Neglected Tropical Disease (NTD) Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Disease
        • 8.3.5.2.2. By Product

9. Middle East & Africa Neglected Tropical Disease (NTD) Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Disease
    • 9.2.2. By Product
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Neglected Tropical Disease (NTD) Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Disease
        • 9.3.1.2.2. By Product
    • 9.3.2. UAE Neglected Tropical Disease (NTD) Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Disease
        • 9.3.2.2.2. By Product
    • 9.3.3. South Africa Neglected Tropical Disease (NTD) Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Disease
        • 9.3.3.2.2. By Product

10. South America Neglected Tropical Disease (NTD) Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Disease
    • 10.2.2. By Product
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Neglected Tropical Disease (NTD) Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Disease
        • 10.3.1.2.2. By Product
    • 10.3.2. Colombia Neglected Tropical Disease (NTD) Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Disease
        • 10.3.2.2.2. By Product
    • 10.3.3. Argentina Neglected Tropical Disease (NTD) Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Disease
        • 10.3.3.2.2. By Product

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Neglected Tropical Disease (NTD) Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. F. Hoffmann-La Roche Ltd
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Sanofi S.A.
  • 15.3. Bayer AG
  • 15.4. GlaxoSmithKline plc
  • 15.5. Novartis AG
  • 15.6. Pfizer, Inc.
  • 15.7. Eisai Co., Ltd.
  • 15.8. Astellas Pharma Inc.
  • 15.9. Takeda Pharmaceutical Company Limited
  • 15.10. Gilead Sciences, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer